Summit Therapeutics Inc. (SMMT)
Company Info
Highlights
$17.42B
-$0.31
-$40.00K
-$172.32M
$2.10 - $36.91
$37.30
21.08%
7.15
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Summit Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Summit Therapeutics Inc. (SMMT) returned 36.12% year-to-date (YTD) and 357.44% over the past 12 months. Over the past 10 years, SMMT returned 8.70% annually, underperforming the S&P 500 benchmark at 10.31%.
SMMT
36.12%
40.24%
16.28%
357.44%
48.32%
8.70%
^GSPC (Benchmark)
-4.26%
11.24%
-5.02%
8.55%
14.02%
10.31%
Monthly Returns
The table below presents the monthly returns of SMMT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 20.48% | -3.77% | -6.77% | 25.04% | 0.70% | 36.12% | |||||||
| 2024 | 50.19% | 15.82% | -8.81% | -5.07% | 120.99% | -10.19% | 38.46% | 20.19% | 68.72% | -15.11% | -0.70% | -3.33% | 583.72% |
| 2023 | -16.47% | -49.30% | -2.78% | -24.57% | 23.48% | 53.99% | -16.33% | -22.86% | 15.43% | 3.74% | 4.64% | 28.57% | -38.59% |
| 2022 | -18.22% | 24.55% | -10.58% | -35.10% | -16.35% | -24.81% | 1.00% | 18.81% | -0.83% | -8.40% | -26.61% | 431.25% | 57.99% |
| 2021 | 48.09% | -2.73% | -13.29% | 8.52% | 22.76% | -4.60% | -1.74% | 8.73% | -37.14% | 2.99% | -1.55% | -47.05% | -42.77% |
| 2020 | -4.38% | -9.80% | 71.74% | 58.23% | 7.73% | -26.49% | 21.89% | -4.70% | -0.29% | -4.94% | 37.61% | 4.44% | 193.75% |
| 2019 | 15.65% | 72.93% | -20.43% | -3.55% | -13.88% | -16.78% | 4.35% | 1.29% | 33.88% | -7.82% | -9.09% | 6.67% | 39.13% |
| 2018 | 23.92% | -14.71% | 10.16% | 1.01% | 2.46% | -81.65% | -6.12% | 2.17% | -5.53% | -23.42% | -23.53% | -11.54% | -89.62% |
| 2017 | 22.31% | 16.62% | 8.72% | -17.14% | 1.09% | 2.43% | 22.74% | -7.94% | -2.49% | -18.09% | 14.49% | -5.86% | 29.44% |
| 2016 | -21.74% | -25.00% | 1.04% | 46.33% | -13.83% | -5.93% | -13.47% | -5.14% | 36.51% | 29.85% | -10.88% | -18.40% | -25.57% |
| 2015 | 21.59% | -15.74% | -0.57% | 1.75% | 22.61% | -8.11% | -12.52% | -2.98% | 3.56% | 9.94% | 12.86% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 97, SMMT is among the top 3% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Summit Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Summit Therapeutics Inc. was 95.75%, occurring on Dec 1, 2022. Recovery took 443 trading sessions.
The current Summit Therapeutics Inc. drawdown is 33.81%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.75% | Sep 12, 2017 | 1316 | Dec 1, 2022 | 443 | Sep 9, 2024 | 1759 |
| -59.8% | Apr 7, 2015 | 366 | Sep 15, 2016 | 13 | Oct 4, 2016 | 379 |
| -47.89% | Sep 16, 2024 | 141 | Apr 8, 2025 | 10 | Apr 23, 2025 | 151 |
| -43.41% | Oct 6, 2016 | 59 | Dec 29, 2016 | 151 | Aug 7, 2017 | 210 |
| -36.06% | Apr 25, 2025 | 1 | Apr 25, 2025 | — | — | — |
Volatility
Volatility Chart
The current Summit Therapeutics Inc. volatility is 61.01%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Summit Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Summit Therapeutics Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -3.3%.
Valuation
The Valuation section provides an overview of how Summit Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for SMMT compared to other companies in the Biotechnology industry. SMMT currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SMMT relative to other companies in the Biotechnology industry. Currently, SMMT has a P/S ratio of 753.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SMMT in comparison with other companies in the Biotechnology industry. Currently, SMMT has a P/B value of 60.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |